In this edition:
Abemaciclib + ET for HR+, HER2-, node-positive, high-risk early breast cancer
TAILORx: 12-year follow-up of ET + chemo vs. ET alone for ER+, HER2-, lymph node-negative breast cancer based on RS
TAM-01: 10-year follow-up of babytam for prevention of recurrence in non-invasive breast cancer
POSITIVE: ET interruption for pregnancy not associated with increased short-term recurrence risk recurrence for early HR+ breast cancer
Addition of platinum to standard neoadjuvant chemo in TNBC
Ribociclib + ET vs. combination chemo for aggressive HR+/HER2− advanced breast cancer
PACE: Fulvestrant, palbociclib & avelumab after CDK4/6i & ET for ER+/HER2 metastatic breast cancer
CAPItello-291: Capivasertib + fulvestrant in aromatase inhibitor-resistant HR+/HER2- advanced breast cancer
Trastuzumab deruxtecan vs. TPC in HER2+ metastatic breast cancer
Please login below to download this issue (PDF)